Real-World Persistence and Costs Among Patients With Chronic Migraine Treated With OnabotulinumtoxinA or CGRP mAbs: A Retrospective Claims Analysis Study (P10-2.004)
Neurology | December 6, 2023 | Volume: 98 | Issue: 18_supplement | Pages: No page available
Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies
Journal of Managed Care & Specialty Pharmacy | September 30, 2023 | Volume: 29 | Issue: 10 | Pages: 1119-1128